Navigation Links
EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting

Supports Local Mechanism of Action of NP-1 in Neuropathic Pain

TARRYTOWN, N.Y., May 03, 2007 /PRNewswire-FirstCall/ -- EpiCept Corporation announced today that it will present new data for EpiCept(TM) NP-1 on Thursday, May 3, 2007 at the 26th Annual Scientific Meeting of the American Pain Society in Washington D.C. EpiCept NP-1 is a patented topical cream formulation of two FDA-approved drugs, 4% amitriptyline and 2% ketamine. NP-1 is a product candidate intended for use in the management of pain resulting from various peripheral neuropathies. Two studies will be presented in poster format by Dennis Everton, RPh., Director of Clinical Development.

Results from a new human pharmacokinetic study of NP-1 designed to assess the pharmacokinetic parameters as well as its safety and tolerability will be presented. The highest observed level of amitriptyline at any time point was 5.91 ng/mL. The highest observed level of ketamine at any time point was 10.7 ng/mL. These levels are far below any known systemic efficacy level and even further below any known systemic level associated with adverse reactions. The study found that NP-1 was safe and well tolerated across all age groups studied. The low systemic levels of amitriptyline and ketamine indicated a local mechanism of action rather than a systemic one. NP-1 is intended as additive therapy in neuropathic pain. This study confirms the independent topical mechanism of NP-1.

Findings will also be presented from a previously disclosed multicenter, double-blind, randomized, placebo controlled Phase II study of NP-1 in treating post-herpetic neuralgia (PHN) in 118 patients. The study was designed to evaluate the analgesic properties of two different strengths of NP-1 compared with placebo in the treatment of PHN. The study met its primary endpoint of an improvement in pain intensity for the high dose strength vs. placebo from baseline to day 21 (p=0.026). Add
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
2. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
4. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
5. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
6. The Past, Present and Future of HLA Typing
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
Post Your Comments:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
(Date:10/20/2014)... Mary,s Medicinals today announced that its 501(c)(3) foundation, ... Operation Grow4Vets , a national, nonpartisan organization focused ... to assist them in living with injuries sustained while ... , An ever-increasing number of medical studies have shown ... pain, Post-traumatic Stress Disorder (PTSD) and Traumatic Brain Injury ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: ... and a live Internet webcast along with a slide presentation ... a.m. PT) to discuss results for the 2010 fourth quarter ... on this call is (877) 295-5743, confirmation code 41335702.  International ...
... Pharmaceuticals Inc. ("Joyant"), a privately-held pharmaceutical company, announced the ... class of anti-cancer therapeutics based upon Smac mimetics.  Smac ... pathway and have broad potential for the treatment of ... The United States Patent and Trademark Office (USPTO) granted ...
Cached Medicine Technology:Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 2
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Having been working ... a good knowledge of customer needs. According to James, one ... covered with dazzling sequins, or with high-low skirts that add ... a huge demand. Recently, LunaDress has unveiled its new selection ... of fact, the company’s brand new items are available in ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... informed about the risks and benefits of taking part ... as vigorously as new medical treatments themselves, a study ... , Informed consent, a mainstay of ethical clinical trials, ... asked to decide whether to participate in research. The ...
... Center say they have evidence that cancer stem cells ... cells and have multiple ways of resisting chemotherapy and ... in the Jan. 1 issue of the journal Cancer ... the Johns Hopkins scientists say, and pave the way ...
... ANGELES, Jan. 11 The Guidebook of ... "the couple" as the main unit for,treatment ... significant emphasis,on the thorough evaluation of biological ... medications) and psychosocial factors (e.g.,presence of depression, ...
... Just in Case, Inc., the makers of,the first ... of their compacts to women,s Non-Profit Groups Nationwide. They ... state will be,chosen to receive 100 JUST IN CASE(R) ... Day., The 10,000 compact give-away will help raise ...
... Conn., Jan. 9 dLifeTV, the first and only,television ... lineup for its eighth season premiering January 20th. Airing,Sundays ... season,s featured,celebrities living with diabetes include TV icon Jerry ... managed fame for over 40 years and his diabetes,for ...
... The World Bank and Conservation International (CI) today ... provided by the Global Environment Facility (GEF), to protect ... including island ecosystems and temperate forests. , These biodiversity ... terrestrial plants and animals, as well as more than ...
Cached Medicine News:Health News:Ways to improve informed consent are testable, study says 2Health News:Stem cells make bone marrow cancer resistant to treatment 2Health News:Stem cells make bone marrow cancer resistant to treatment 3Health News:A New Book on Sexual Medicine Calls Attention to 'The Couple' and Presents State-of-the Art Treatments for Sexual Dysfunction 2Health News:Teen Pregnancy Epidemic Another Reason for Women to Carry Condoms. Just in Case, Inc. Announces 10,000 Chic Condom Compact Give-Away to Women's Non-Profits Nationwide. 2Health News:dLIFETV Premieres Eighth Season With Baseball's 'Comeback Player' Dmitri Young and Leave It To Beaver's Jerry Mathers 2Health News:Global Environment partners provide additional $20 million to protect endangered habitats 2
... surface preparation is the Leica SM2500 sledge ... ,Ultramilling is often a viable alternative to ... preparation. Especially with difficult specimens, where hard ... side in one specimen block, the results ...
... The Trellis Infusion Catheter enables the physician ... physician-specified fluid, and disperse the agent by ... The Trellis is a multi-lumen catheter with ... end and infusion holes located between these ...
... The SENSAR® Acrylic IOL with OptiEdge ... performance, long-term refractive stability, and excellent handling. ... has had no reports of vacuoles; the ... internal reflections and provide 360 degrees of ...
... acrylic foldable single-piece posterior chamber lenses are ... human crystalline lens in the visual correction ... age and older. The optical portion consists ... material. These lenses have biconvex optics and ...
Medicine Products: